Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 138,770,784
  • Shares Outstanding, K 2,262,690
  • Annual Sales, $ 26,145 M
  • Annual Income, $ 3,439 M
  • 60-Month Beta 0.72
  • Price/Sales 5.17
  • Price/Cash Flow 13.60
  • Price/Book 2.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 1.54
  • Number of Estimates 4
  • High Estimate 1.59
  • Low Estimate 1.51
  • Prior Year 1.17
  • Growth Rate Est. (year over year) +31.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.16 +6.75%
on 07/10/20
62.97 -3.10%
on 08/06/20
+0.73 (+1.21%)
since 07/07/20
3-Month
54.07 +12.85%
on 06/15/20
65.34 -6.61%
on 05/15/20
-0.02 (-0.03%)
since 05/07/20
52-Week
45.32 +34.64%
on 08/15/19
68.34 -10.71%
on 01/22/20
+14.78 (+31.96%)
since 08/07/19

Most Recent Stories

More News
Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

JNJ : 148.60 (+0.71%)
PFE : 38.45 (+0.47%)
MRK : 81.02 (-0.04%)
LLY : 152.93 (+0.03%)
BMY : 61.02 (-0.51%)
PPH : 63.76 (-0.93%)
PJP : 66.72 (+0.09%)
IHE : 163.82 (+0.43%)
XPH : 44.73 (+0.58%)
FTXH : 24.46 (+0.22%)
Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact

Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.

BMY : 61.02 (-0.51%)
EBS : 130.66 (+2.91%)
HZNP : 76.06 (+5.32%)
CLVS : 5.42 (-13.00%)
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress

Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.

PFE : 38.45 (+0.47%)
MRK : 81.02 (-0.04%)
BMY : 61.02 (-0.51%)
NKTR : 21.85 (+1.58%)
Acceleron (XLRN) Reports Narrower-Than-Expected Q2 Loss

Acceleron (XLRN) posts a narrower-than-expected Q2 loss owing to increased revenues.

INCY : 96.93 (-0.33%)
NVS : 82.91 (-0.60%)
BMY : 61.02 (-0.51%)
XLRN : 99.12 (-6.89%)
Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates

Exelixis (EXEL) beats on earnings and sales in the second quarter.

RHHBY : 43.0100 (-0.97%)
MRK : 81.02 (-0.04%)
EXEL : 22.36 (-1.97%)
BMY : 61.02 (-0.51%)
Company News for Aug 7, 2020

Companies In The News: BMY, CRON, BDX, LNG.

BDX : 256.41 (-1.23%)
BMY : 61.02 (-0.51%)
LNG : 53.34 (+0.41%)
CRON : 5.70 (-2.90%)
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

PPH : 63.76 (-0.93%)
LLY : 152.93 (+0.03%)
BMY : 61.02 (-0.51%)
ABBV : 92.92 (+0.38%)
PJP : 66.72 (+0.09%)
IHE : 163.82 (+0.43%)
Bristol-Myer Sqb Shares (BMY)

SmarTrend identified a Downtrend for Bristol-Myer Sqb (NYSE:BMY) on May 27th, 2020 at $59.82. In approximately 2 months, Bristol-Myer Sqb has returned 2.53% as of today's recent price of $61.33.

BMY : 61.02 (-0.51%)
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates

Bristol Myers (BMY) delivered earnings and revenue surprises of 11.64% and 0.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

BMY : 61.02 (-0.51%)
Bristol-Myer Sqb Set to Possibly Pullback After Yesterday's Rally of 3.20%

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $60.42 to a high of $62.97. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of...

BMY : 61.02 (-0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products. It offers products which includes hematology, oncology, cardiovascular and immunology. Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, is based in...

See More

Key Turning Points

2nd Resistance Point 62.26
1st Resistance Point 61.64
Last Price 61.02
1st Support Level 60.41
2nd Support Level 59.80

See More

52-Week High 68.34
Last Price 61.02
Fibonacci 61.8% 59.55
Fibonacci 50% 56.83
Fibonacci 38.2% 54.11
52-Week Low 45.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar